Iktos Appoints Dr. Ashiq H. Khan as Chief Business Officer to Propel Global Expansion
Paris, Wednesday, 3 September 2025.
Iktos, a leader in AI-driven drug discovery, names Dr. Ashiq H. Khan as Chief Business Officer, aiming to boost global growth and strategic partnerships, leveraging his extensive pharma industry experience.
New Leadership to Drive Strategic Growth
Dr. Ashiq H. Khan, appointed as the Chief Business Officer of Iktos, brings over 15 years of experience in scaling computational and drug discovery platform businesses. With a proven track record of closing over $6 billion in high-value deals and driving significant revenue growth, Dr. Khan is well-positioned to lead Iktos’ global commercial expansion in AI-driven drug discovery and pharmaceutical collaborations [1].
Expanding Iktos’ Global Presence
Iktos, a pioneer in AI-driven drug discovery, aims to leverage Dr. Khan’s expertise to enhance its market presence and forge new strategic partnerships within the pharmaceutical industry. The company, which has successfully completed over 60 projects, is poised to capitalize on its cutting-edge AI and robotics platforms to accelerate drug discovery processes while maintaining cost-efficiency [1].
Recent Achievements and Future Plans
In recent years, Iktos has made significant strides in strengthening its financial and technological foundations. In 2023, the company completed a €15.5 million Series A financing round, co-led by M Ventures and Debiopharm Innovation [1]. The subsequent acquisition of Synsight in 2024 further augmented its capabilities with advanced cellular imaging and biological screening technologies [1]. Looking ahead, Iktos plans to utilize a €2.5 million grant from the European Innovation Council Accelerator to advance its integrated AI and robotics platform, with potential follow-on funding of €5 million [1].
Commitment to Innovation in Drug Discovery
Iktos remains dedicated to advancing the discovery of transformative therapies, enabling partners to bring new treatments to patients more rapidly. Dr. Khan’s appointment underscores Iktos’ commitment to maintaining its leadership position at the intersection of AI, robotics, and pharmaceutical innovation. This strategic focus aims to offer unparalleled opportunities for pharmaceutical companies in streamlining drug discovery processes [1].